Gyre Therapeutics
GYRE
56 hedge funds and large institutions have $236M invested in Gyre Therapeutics in 2018 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 18 increasing their positions, 2 reducing their positions, and 7 closing their positions.
5,056% more capital inflows, than outflows
Capital inflows: $160M | Capital outflows: $3.11M
800% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 2
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
300% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 7
60% more funds holding
Funds holding: 35 → 56 (+21)
52.62% more ownership
Funds ownership: 24.4% → 77.02% (+53%)
55% less call options, than puts
Call options by funds: $2.3M | Put options by funds: $5.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sio Capital Management
New York
|
+$23.6M |
| 2 |
Deerfield Management
New York
|
+$20.7M |
| 3 |
Acuta Capital Partners
Redwood City,
California
|
+$17.5M |
| 4 |
Avoro Capital Advisors
New York
|
+$15.5M |
| 5 |
RA Capital Management
Boston,
Massachusetts
|
+$12.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pura Vida Investments
New York
|
-$818K |
| 2 |
Raymond James & Associates
St Petersburg,
Florida
|
-$585K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$583K |
| 4 |
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$510K |
| 5 |
Kalos Management
Alpharetta,
Georgia
|
-$222K |
GYRE Hedge Fund Activity: Q1 2018 in Review
56 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2018, worth a combined $236M — up 496% from $39.7M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new GYRE positions and 7 closed out — a net gain of 21 holders — while 18 added to existing stakes and 2 trimmed.
The largest buyer was Sio Capital Management, adding an estimated $23.6M. The largest seller was Pura Vida Investments, exiting entirely with an estimated $818K sold.
- 56 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2018, up from 35 in Q4 2017.
- Funds reported $236M of Gyre Therapeutics stock for Q1 2018, up 496% quarter-over-quarter.
- 28 funds opened new Gyre Therapeutics positions in Q1 2018 and 7 closed out, a net change of +21 holders.
- The largest Gyre Therapeutics buyer in Q1 2018 was Sio Capital Management, an estimated $23.6M added.
- The largest Gyre Therapeutics seller in Q1 2018 was Pura Vida Investments, an estimated $818K sold.
Based on aggregated 13F filings for Q1 2018.